Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: A preliminary report

被引：32

作者：

Oh, WK ^{[1
]}

George, DJ

Kaufman, DS

Moss, K

Smith, MR

Richie, JP

Kantoff, PW

机构：

[1] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Dept Adult Oncol, Boston, MA 02115 USA

[2] Massachusetts Gen Hosp, Dept Adult Oncol, Boston, MA 02114 USA

[3] Brigham & Womens Hosp, Div Urol Surg, Boston, MA 02115 USA

[4] Dana Farber Canc Inst, Div Urol Surg, Boston, MA 02115 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 04期

关键词：

D O I：

10.1016/S0093-7754(01)90153-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：40 / 44

页数：5

共 20 条

[1]

BEER TM, 2000, P AN M AM SOC CLIN, V19, P348

[2] Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].

Bolla, M ;

Gonzalez, D ;

Warde, P ;

Dubois, JB ;

Mirimanoff, RO ;

Storme, G ;

Bernier, J ;

Kuten, A ;

Sternberg, C ;

Gil, T ;

Collette, L ;

Pierart, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300

[3] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].

D'Amico, AV ;

Whittington, R ;

Malkowicz, SB ;

Schultz, D ;

Blank, K ;

Broderick, GA ;

Tomaszewski, JE ;

Renshaw, AA ;

Kaplan, I ;

Beard, CJ ;

Wein, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974

[4] Results of radical prostatectomy in men with locally advanced prostate cancer: Multi-institutional pooled analysis [J].

Gerber, GS ;

Thisted, RA ;

Chodak, GW ;

Schroder, FH ;

Frohmuller, HGW ;

Scardino, PT ;

Paulson, DF ;

Middleton, AW ;

Rukstalis, DB ;

Smith, JA ;

Ohori, M ;

Theiss, M ;

Schellhammer, PF .

EUROPEAN UROLOGY, 1997, 32 (04) :385-390

[5] Adjuvant and neoadjuvant treatment of breast cancer [J].

Gianni, L ;

Valagussa, P ;

Zambetti, M ;

Moliterni, A ;

Capri, G ;

Bonadonna, G .

SEMINARS IN ONCOLOGY, 2001, 28 (01) :13-29

[6] Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer [J].

Hainsworth, JD ;

Burris, HA ;

Erland, JB ;

Thomas, M ;

Greco, FA .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2164-2168

[7] Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study [J].

Kantoff, PW ;

Halabi, S ;

Conaway, M ;

Picus, J ;

Kirshner, J ;

Hars, V ;

Trump, D ;

Winer, EP ;

Vogelzang, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2506-2513

[8] Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer [J].

Kelly, WK ;

Curley, T ;

Slovin, S ;

Heller, G ;

McCaffrey, J ;

Bajorin, D ;

Ciolino, A ;

Regan, K ;

Schwartz, M ;

Kantoff, P ;

George, D ;

Oh, W ;

Smith, M ;

Kaufman, D ;

Small, EJ ;

Schwartz, L ;

Larson, S ;

Tong, W ;

Scher, H .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :44-53

[9] Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma [J].

Kreis, W ;

Budman, DR ;

Fetten, J ;

Gonzales, AL ;

Barile, B ;

Vinciguerra, V .

ANNALS OF ONCOLOGY, 1999, 10 (01) :33-38

[10] EXTENDED EXPERIENCE WITH RADICAL PROSTATECTOMY FOR CLINICAL STAGE T3 PROSTATE-CANCER - OUTCOME AND CONTEMPORARY MORBIDITY [J].

LERNER, SE ;

BLUTE, ML ;

ZINCKE, H .

JOURNAL OF UROLOGY, 1995, 154 (04) :1447-1452

← 1 2 →